SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is dominating financial discussions, fueled by renewed excitement around online mentions of a key figure from its historical short squeeze. The community is actively debating the company's strong cash position and its continued high short interest, as many believe short sellers face significant challenges.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA) is trending as its live integration with Bridge, a Stripe-owned fiat anchor, positions it as crucial global financial plumbing. The community is actively discussing its impressive 11M+ transactions per second and compliance-first architecture, making it an attractive, yet undervalued, asset. Many see it as a complementary layer poised to enhance institutional flows and real-world asset settlement across the broader financial ecosystem.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is actively discussed following a high-profile dinner between its CEO and a prominent political figure, which has ignited speculation about potential strategic alignments. Community sentiment is mixed, with bulls emphasizing the company's long-term vision in AI and robotics, while bears focus on recent delivery challenges and increasing EV market competition, alongside broader geopolitical events impacting oil prices and EV adoption.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is trending amidst widespread speculation that its advanced AI and data analytics platforms were instrumental in a recent high-profile US military operation in Venezuela. This has ignited strong bullish sentiment, with discussions centering on potential new government contracts and its critical national security capabilities. However, a significant portion of the community remains cautious, emphasizing the stock's high valuation and debating the long-term impact of such an event on its fundamental trajectory.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is heavily trending due to immediate geopolitical developments in Venezuela, with the US indicating its intention for American oil companies to play a significant role in the nation's vast oil reserves. The community is buzzing with both bullish sentiment, anticipating a substantial upside given Chevron's unique operational presence, and cautious outlooks debating the long-term implications of potential oil oversupply. Many see Chevron as uniquely positioned to benefit, with discussions focusing on how it could leverage existing infrastructure and licenses in this significant energy shift.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

ExxonMobil is trending as market participants anticipate the energy giant will significantly benefit from recent geopolitical developments in Venezuela, potentially gaining access to the nation's immense oil reserves. The community is buzzing with talk of a major breakout for XOM, fueled by expectations that US oil companies will play a key role in rebuilding and profiting from the world's largest crude supplies. This excitement is driving conversation around the broader energy sector's potential upside.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens is trending due to surging institutional interest, highlighted by U.S. Bank's exploration of stablecoin issuance on its network and XLM's inclusion in new ETFs. The community is actively discussing the network's ongoing upgrades and its competitive standing against emerging high-performance, compliance-focused platforms. This collective focus is driving bullish sentiment, anticipating XLM's pivotal role in the evolving digital financial infrastructure.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust (SPY) is trending as market participants react to geopolitical developments concerning Venezuela. Community sentiment is sharply divided, with many anticipating a significant market rally spurred by perceived new US energy leverage and strength, while others express caution over potential global instability and a looming market correction. This situation is driving intense debate around oil prices and the broader economic outlook, shaping diverse expectations for the week ahead.

SLB Ltd. engages in the provision of energy technology. It operates through the following business segments: Digital and Integration, Reservoir Performance, Well Construction, and Production Systems. The Digital and Integration segment involves the combination of digital solutions and data products with its Asset Performance Solutions. The Reservoir Performance segment consists of technologies and services for productivity and performance optimization. The Well Construction segment includes the full portfolio of products and services for well placement and performance, drilling, and wellbore assurance. The Production Systems segment focuses on the development of technologies and provides services to production and recovery from subsurface reservoirs to the surface, into pipelines, and to refineries. The company was founded by Conrad Schlumberger and Marcel Schlumberger in 1926 and is headquartered in Houston, TX.

SLB Ltd.

Schlumberger Ltd.

Schlumberger (SLB) is trending as the community anticipates significant demand for oilfield services following developments in Venezuela, with expectations that SLB will play a key role in rebuilding the nation's oil infrastructure. This optimism is further fueled by a recently secured 5-year contract with Aramco and the company's expanding AI/digitalization initiatives. Traders are noting bullish technical setups, pointing to potential continued upside for SLB and the broader energy services sector.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is at the center of intense acquisition speculation from major industry players like SpaceX and Amazon, who are vying for its highly coveted Band n53 globally harmonized spectrum. The community is keenly focused on how this unique spectrum, bolstered by XCOM RAN technology, is crucial for emerging applications such as drone delivery and direct-to-device connectivity, driving conversations about a potentially massive valuation. Recent strategic developments and regulatory activities signal a pivotal moment for the company in the converging satellite and terrestrial communications landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism

CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology

Market rotations are as old as Wall Street itself. When capital exits overheated sectors like big tech, it often finds its way into undervalued industries ripe for rediscovery. The latest shift, away from pricey artificial intelligence and semiconductor stocks, has once again turned investors&#8217; attention toward biotechnology. And within biotech, the most compelling breakthroughs are not in computing or automation, but in humanity&#8217;s longest-standing battle: defeating cancer.As institutional money seeks new opportunities, healthcare and biotech have emerged as natural ...

<ul class="summary-bullets"><li>MFN pricing extended nationwide through Medicaid and to future new medicines.</li><li>Steep direct-to-patient discounts rolled out via TrumpRx, including $35 insulin.</li><li>Additional pharma companies, including Johnson &amp; Johnson, are expected to ink similar deals next week.</li></ul><p>U.S. President Donald Trump on Friday announced nine new agreements with pharmaceutical companies to lower prescription drug prices for Americans to the lowest levels paid in other developed nations, under what the administration calls a “most-favored-nation” (MFN) pricing framework.</p><p>With these additions, 14 of the 17 pharmaceutical companies targeted by the administration in August have now signed on.</p><h2 class="st-heading-2"><strong>Big Pharma Roster Expands</strong></h2><p>The companies named in Friday’s agreements are Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi.</p><p>Trump said additional companies, including Johnson &amp; Johnson, are expected to announce similar agreements next week, as the administration continues to expand the program.</p><h2 class="st-heading-2"><strong>Medicaid Savings And Future Drug Pricing</strong></h2><p>The White House said the agreements apply to drugs used to treat an array of expensive, long-term conditions including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, hepatitis B and C, HIV and certain cancers.</p><p>The administration said every state Medicaid program in the U.S. will benefit from MFN prices on products from the nine companies, which it estimates will save billions of dollars. The agreements also require MFN pricing for all new innovative medicines these companies bring to market.</p><p>Trump also floated the idea of calling a meeting with insurance companies to discuss further ways to lower healthcare costs, suggesting insurers could significantly reduce prices or face alternative approaches that would direct savings to consumers.</p><h2 class="st-heading-2"><strong>Deep Discounts Via TrumpRx</strong></h2><p>The administration said the companies are required to offer medicines at steep discounts off list prices when selling directly to American patients through TrumpRx, a government-backed direct-to-patient drug purchasing platform.</p><p>The administration said patients would see steep price cuts, citing examples such as Amgen’s Repatha at $239 versus&nbsp;list price of $573, Bristol Myers Squibb’s Reyataz at $217 versus $1,449, and Sanofi’s Plavix at $16 versus $756, alongside similar reductions for drugs from Gilead, GSK, Merck and Novartis. The administration also said Sanofi will list its insulin products on TrumpRx at $35&nbsp;for every&nbsp;month’s supply.</p><h2 class="st-heading-2"><strong>Drugmakers Pledge Domestic Investment</strong></h2><p>Trump said the participating companies have committed to invest at least $150 billion collectively in U.S. pharmaceutical manufacturing in the near term.</p><p>The administration also said several companies will donate active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve to strengthen emergency preparedness. GSK will contribute 98.8 kg of Albuterol, Bristol Myers Squibb will contribute tablets representing 6.5 tons of Apixaban, and Merck will contribute 3.5 tons of Ertapenem.</p><h2 class="st-heading-2"><strong>How Did Stocktwits React?</strong></h2><p>On Stocktwits, Health Care Select Sector SPDR Fund (XLV) showed 'bearish' retail sentiment amid 'high' message volume, while iShares Global Healthcare ETF (IXJ) saw 'bullish' sentiment with 'high' activity.</p><p><a href="https://stocktwits.com/symbol/XLV">XLV</a> and&nbsp;<a href="https://stocktwits.com/symbol/IXJ">IXJ</a> have risen 14% so far this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Trump announced his plan to lower drug prices would tie their cost to drug prices paid in foreign nations. (Photo by Andrew Harnik/Getty Images)

Trump Locks In Drug-Price Cuts With Roche, Novartis, Merck — More Big Pharma Deals Coming Next Week

The deals expand the pricing program to several drugmakers in exchange for temporary tariff relief.

Equity

Can Merck Successfully Steer Through the Upcoming Headwinds?

MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.

PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

<ul class="summary-bullets"><li>The talks follow the administration’s push to lower U.S. drug prices using trade and regulatory leverage.</li><li>Pfizer and AstraZeneca have already reached agreements, while several other major drugmakers are still weighing potential deals.</li><li>Novartis and Roche have highlighted U.S. investment and manufacturing commitments.</li></ul><p>Novartis' U.S.-listed stock rose on Wednesday as investors weighed reports of impending U.S. drug pricing deals tied to the company.</p><p>The announcement is expected as soon as Friday and could include Roche, though details are still being finalized and additional drugmakers may be added, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-17/novartis-roche-near-us-drug-price-deal-in-easing-of-swiss-trade-tensions">report</a> by Bloomberg.</p><h2 class="st-heading-2"><strong>Trump’s Push On Drug Prices</strong></h2><p>In August,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-turns-up-heat-on-big-pharma-ce-os-to-slash-drug-prices-within-60-days-but-retail-traders-don-t-flinch/chr3jLYRdGW">Trump sent letters to 17 pharmaceutical companies</a> demanding that they cut prices for U.S. government insurance programs and align domestic pricing more closely with what patients pay in other developed countries. The letters also called for companies to make medicines available through a Trump-branded direct-to-consumer platform and commit to not charging Americans more than foreign markets under a “most-favored-nation” pricing framework.</p><p>In exchange, companies were offered multiyear relief from threatened tariffs and some potential regulatory measures. The administration has said it is using trade policy as leverage to force price reductions, arguing that Americans pay more than triple what patients in other developed nations pay for the same drugs.</p><h2 class="st-heading-2"><strong>Who Has And Hasn’t Cut Deals</strong></h2><p>Pfizer and AstraZeneca have already struck agreements with the administration in recent months, but many other drugmakers are still on the sidelines. Companies such as AbbVie, Bristol-Myers Squibb, Gilead Sciences, Amgen, Johnson &amp; Johnson, Merck, Regeneron Pharmaceuticals and Sanofi have yet to announce any deals.</p><p>Novartis said in a statement to Bloomberg it is in talks with the administration and is committed to lowering U.S. drug costs while addressing price gaps with other developed countries. Meanwhile, Roche’s Genentech unit said it supports efforts to reduce U.S. prices while urging other nations to better reward biopharmaceutical innovation.</p><p>The White House cautioned that no deal is final. “Until officially announced by President Trump or the Administration, any reporting about potential dealmaking is speculation,” spokesman Kush Desai told the news outlet.</p><h2 class="st-heading-2"><strong>Manufacturing Commitments&nbsp;</strong></h2><p>Domestic manufacturing has played a central role in negotiations. Novartis has stepped up its U.S. footprint, with CEO Vas Narasimhan recently attending the opening of a new manufacturing facility in North Carolina alongside FDA Commissioner Marty Makary.</p><p>The company plans to invest $23 billion in the U.S. over the next five years and generate about 41% of its revenue from the market, led by drugs such as Entresto. Roche has also committed to expanding in the U.S., pledging $50 billion in investment and deriving nearly half of its revenue from the country, driven by treatments including Ocrevus and Tecentriq.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Novartis was ‘bearish’ with ‘low’ message volume, while Roche was ‘bullish’ amid ‘high’ message volume.</p><p>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/NVS">Novartis’ U.S.-listed shares</a> have risen 42%, while&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s U.S.-listed stock</a> has also gained 45% over the same period.</p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?

BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.

Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?

Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

RHHBY
Roche Holdings AG ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RHHBY News

RHHBYRoche Holdings AG ADR